A recombinant form of the naturally-occurring cytokine interferon-alpha (IFN-a) that has a modified spatial configuration, with immunomodulating, antiviral and antineoplastic activities. Upon administration of recombinant super-compound interferon (rSIFN-co), this agent binds to IFN-specific cell surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. The 3-dimensional conformational change improves efficacy and causes fewer side effects compared to IFN-a. Check for active clinical trialsusing this agent.